• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study Clinical Trial
In the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study, 4.8 years’ losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke. However, there was no difference in myocardial infarction (MI), possibly related to greater reduction in myocardial oxygen demand by atenolol-based treatment. Myocardial oxygen demand was assessed indirectly by the left ventricular massxwall stressxheart rate (triple product) in 905 LIFE participants. The triple product was included as time-varying covariate...
Source: Hypertension - October 7, 2015 Category: Cardiology Authors: Devereux, R. B., Bang, C. N., Roman, M. J., Palmieri, V., Boman, K., Gerdts, E., Nieminen, M. S., Papademetriou, V., Wachtell, K., Hille, D. A., Dahlof, B. Tags: Hypertrophy, Other etiology Clinical Trial Source Type: research

Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients With Left Ventricular Hypertrophy Original Articles
Conclusions— Development of new-onset AF identifies hypertensive patients at increased risk of SCD. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00338260.
Source: Circulation: Arrhythmia and Electrophysiology - April 16, 2013 Category: Cardiology Authors: Okin, P. M., Bang, C. N., Wachtell, K., Hille, D. A., Kjeldsen, S. E., Dahlof, B., Devereux, R. B. Tags: Clinical Studies, Arrhythmias, clinical electrophysiology, drugs, Epidemiology Original Articles Source Type: research